Carl Schmid and Frank J. Palella, MD, review unmet needs for the uptake of HIV PrEP therapy for at-risk patient populations. Ryan Haumschild, PharmD, MS, MBA: Carl, which groups of eligible patients ...

Frank J. Palella, MD, and Ryan Bitton, PharmD, MBA, provide insight on the typical patient journey for someone who is going to receive HIV PrEP therapy and the recent increase in use of the therapy.

Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV ...

An injectable form of PrEP has been given “breakthrough therapy” designation by the FDA. PrEP, or pre-exposure prophylaxis, uses antiretroviral therapies designed to combat HIV to help prevent ...

The federal government may have contributed far more to the development of HIV pre-exposure prophylaxis (PrEP) than previously estimated, researchers reported. While previous estimates said the ...